重新定义肿瘤学的治疗终点。
Redefining the Treatment Endpoints in Oncology.
机构信息
Department of Surgical Oncology, All India Institute of Medical Sciences, Rishikesh, India.
出版信息
Oncologist. 2021 Mar;26(3):e521. doi: 10.1002/onco.13688. Epub 2021 Feb 12.
Abstract
The jargon and survival data used by oncologists to communicate with patients may not be fully understood by a patient, resulting in a hasty decision without a proper understanding of its implications. This letter to the editor calls for more patient‐friendly language to improve communication.
摘要
肿瘤学家用于与患者沟通的行话和生存数据可能未被患者充分理解，导致在没有充分了解其含义的情况下仓促做出决定。这封给编辑的信呼吁使用更适合患者的语言来改善沟通。
相似文献
1
Redefining the Treatment Endpoints in Oncology.重新定义肿瘤学的治疗终点。
Oncologist. 2021 Mar;26(3):e521. doi: 10.1002/onco.13688. Epub 2021 Feb 12.
2
Redefining perspectives, processes, and performance in oncology services for the year 2000.
J Oncol Manag. 1997 Mar-Apr;6(2):11-8.
3
The competencies of a cancer educator: redefining the future.癌症教育工作者的能力：重新定义未来。
J Cancer Educ. 2015 Mar;30(1):190-2. doi: 10.1007/s13187-015-0793-4.
4
Patients' Understanding of Oncology Clinical Endpoints: Environmental Scan and Focus Groups.患者对肿瘤学临床终点的理解：环境扫描和焦点小组。
Oncologist. 2020 Dec;25(12):1060-1066. doi: 10.1634/theoncologist.2020-0402. Epub 2020 Aug 27.
5
Integrating subgroups with mixed-type endpoints in early phase oncology trials.整合早期肿瘤试验中具有混合终点的亚组。
Stat Methods Med Res. 2020 Feb;29(2):498-507. doi: 10.1177/0962280219840050. Epub 2019 Apr 4.
6
[Advanced practice nurse in oncology].肿瘤学高级执业护士
Soins. 2019 Dec;64(841):52-55. doi: 10.1016/j.soin.2019.10.010.
7
Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology.篮子研究：在基因组驱动的肿瘤学时代重新定义临床试验。
Annu Rev Med. 2018 Jan 29;69:319-331. doi: 10.1146/annurev-med-062016-050343. Epub 2017 Nov 9.
8
"Timely communication" needs redefining.“及时沟通”需要重新定义。
Can Fam Physician. 2003 Oct;49:1272-3.
9
Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies.肿瘤药物审批：在突破性治疗时代评估终点和证据。
Oncologist. 2017 Jul;22(7):762-767. doi: 10.1634/theoncologist.2017-0152. Epub 2017 Jun 2.
10
Regarding "Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies".关于“肿瘤药物审批：在突破性疗法时代评估终点和证据”。
Oncologist. 2017 Jul;22(7):757-758. doi: 10.1634/theoncologist.2017-0202. Epub 2017 Jun 2.
本文引用的文献
1
Patients' Understanding of Oncology Clinical Endpoints: Environmental Scan and Focus Groups.患者对肿瘤学临床终点的理解：环境扫描和焦点小组。
Oncologist. 2020 Dec;25(12):1060-1066. doi: 10.1634/theoncologist.2020-0402. Epub 2020 Aug 27.
2
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.新辅助放化疗联合手术与单纯手术治疗食管或食管胃交界癌（CROSS）：一项随机对照临床试验的长期结果。
Lancet Oncol. 2015 Sep;16(9):1090-1098. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5.
3
New cancer drugs at the cost of bankruptcy: will the oncologist tell the patients the benefit in terms of days/weeks added to life?以破产为代价的新型抗癌药物：肿瘤学家会告知患者其在延长生命天数/周数方面的益处吗？
Oncologist. 2014 Dec;19(12):1291. doi: 10.1634/theoncologist.2014-0263.
Zotero 插件